From 5/2001 to 12/2004, we treated 27 cases of MI with streptokinase. We succeeded in 17 cases (63%). Two out of ten patients did not received Streptokinase due to contraindication died. If PCI is unavailable, the use of fibrinolytic agent such as Streptokinase can diminish mortality rate and complication of myocardial infarction.
Myocardial Infarction ; Streptokinase ; Therapeutics

Background: Standard treatment for pleural infection includes of drainage and antibiotics. Chest tube drainage often fails if the fluid is loculated by fibrinous adhesions. Intrapleural fibrinolysis may facilitate pleural drainage. Objective: To evaluate the role of Streptokinase (STK) in the treatment of empyema and exudative pleural effusions. Subjects and method: A study included 34 patients (21 patients with exudative pleural effusions, 13 patients with empyema), aged 15-77 years. All patients received intrapleural STK daily with dose of 300.0000-500.000 UI for empyema and 300.000 UI for exudative pleural effusions. Response was assessed by clinical outcome, pleural fluid drainage, chest radiography, pleural ultrasound. Results: Mean pleural fluid drainage after STK instillation was higher in all patients. Pleural fluid drainage was 640 \xb1 494 ml before STK instillation and 823 \xb1 755 ml after STK instillation for empyema; 765 \xb1 691 ml before STK instillation and 1,033 \xb1 757 ml after STK instillation for exudative pleural effusions. The success rate of clinical outcome was 100%. Only 2 patients required decortications. Fever occurred in 3 patients (8.8%) and allergy in 1 patient (3%). Conclusions: Intrapleural STK was safe and effective in the treatment of empyema and exudative pleural effusions. STK prevents pleural adhesions and reduces the risks for surgery.
Streptokinase/ therapeutic use ; Empyema ; Pleural/therapy ; Pleural Effusion/ therapy

A Case of Eales' disease in a 36 years, old R.O.K. officer, male, is presented in this report. This patient has been suffered from Eales' disease for these 3 years. Although the recovery from this disease was occurred two times previously, it was resulted as Complete blindness of O. D. due to the Complications of this disease and poor visual acuity of O. S. on account of marked vitreous opacity and retinal hemorrhage in spite of intensive treatment with anti-tuber culous agents, steroids, varidase and subconjunctival injection of 3% Sodiumchloride solution.
Blindness ; Humans ; Male ; Retinal Hemorrhage ; Steroids ; Streptodornase and Streptokinase ; Visual Acuity

1. A comparative studies of the effects of Varidase and Urokinase on the experimental hyphema produced by the injection of rabbits auto-blood were performed in 20 eyes. 2. Subconjunctival injection of each enzymes were perfomed 1 hour after production of hyphema, and thereafter repeated once daily for 10 days. 3. Varidase increased the rate of absorption of hyphema, but Urokinase had no effect. 4. No side reactions were observed following the subconjunctival injection of these enzymes.
Absorption* ; Hyphema* ; Rabbits* ; Streptodornase and Streptokinase ; Urokinase-Type Plasminogen Activator

The lysing capability urokinase(UK) and streptokinase (SK) in intracerebral hematoma were examined in vitro and in a rabbit model. Intracerebral-intraventricular(IC-IV) hematomas were created by stereotaxically injecting 0.2ml of clotted human blood into the frontal lobe and lateral ventricle of a total of 87 house rabbits(weighing 1.5-2.7kg). Control animals received 0.2ml of physiologic saline infused into the clot, and the experimental group received an equal volume of UK solution(50,000units/ml), SK solution(50,000units/ml), UK-SK mixture(0.1ml of UK solution, 0.1ml of SK solution) respectively after the clot infusion. Forty two animals were sacrificed at 3 hours and 45 animals at 24 hours after infusion, The results obtained were as follows: 1) At 3 hours, clot lysis had been achieved in 8(67%) of 12 UK-infused animals, 5(36%) of 14 SK-infused animals and 6(60%) of 10 UK-SK-infused animals as compared to zero of 6 controls. 2) At 24 hours, clots had been lysed in 11(73%) of 15 UK-infused animals, 8(67%) of 12 SK-infused animals, 8(67%) of 12 UK-SK-infused animals and in 2(33%) of 6 controls. 3) There was mild inflammatory reaction by the clotted blood, but no additional histologic abnormality by thrombolytic agents(UK,SK) on microscopic examination. 4) Therefore we suggest that UK, SK or UK-SK mixture may be effectively used for the lysis of clotted intracerebral hematoma in the rabbit model and UK, UK-SK mixture are more effective than SK at 3 hours.
Animals ; Fibrinolytic Agents* ; Frontal Lobe ; Hematoma* ; Humans ; Lateral Ventricles ; Streptokinase ; Urokinase-Type Plasminogen Activator

OBJECTIVE: In most cases, the postoperative course of a chronic subdural hematoma (CSDH) is good, but CSDHs sometimes remain after the inserted catheter is removed, and the outcomes of such remnant hematomas are unclear. As oral streptokinase-streptodornase (OSS) has anti-inflammatory and hematologic effects, we assessed the effects of OSS on remnant CSDHs through a retrospective analysis of clinical data. METHODS: This study included 101 patients with traumatic CSDH who had remnant CSDH after burr-hole trephination with the closed drainage system between October 2009 and December 2012. We assessed the clinical outcomes, remnant CSDH volume, and recurrence rate from computed tomography scans in order to evaluate the effects of OSS. RESULTS: No significant differences were found in the changes in remnant hematoma volume between the OSS-treated and non-treated groups (p=0.531). The reoperation rate because of was 5.4% (2 patients) in the OSS-treated group and 6.3% (4 patients) in the non-treated group. The number of patients requiring reoperation did not differ between the groups (p=0.658). CONCLUSION: OSS treatment was not associated with a significant reduction in the remnant CSDH volume or recurrence rate after burr-hole drainage. Thus, there seems to be no basis for using OSS in CSDH patients.
Catheters ; Drainage ; Hematoma ; Hematoma, Subdural, Chronic* ; Humans ; Recurrence ; Reoperation ; Retrospective Studies ; Streptodornase and Streptokinase ; Trephining

The bacterial protein streptokinase binds to LD-M subunits, which shares a small region of homology with the site on plasminogen to which streptokinase is known to bind. We found an extra band of LD activity in CSF in a patient, suffering from meningitis due to Streptococcus pneumoniae. We performed a LD isoenzyme electrophoresis of the serum mixed with supernates from cultured broth of several species of streptococci. To investigate the effect on serum LD activity, we analyzed LD activity after the mixing of the serum with products of S. pneumoniae. S. pneumoniae, groups A and C beta hemolytic streptococci, revealed the extra band of LD activity at the origin site. The supernates of cultured broth of S. pneumoniae inhibited LD activity of the serum. Streptokinase or streptokinase-like substances can form complexes with LD in vivo after streptococcal infection, with consequent alteration of the LD isoenzyme pattern.
Bacterial Proteins ; Electrophoresis ; Humans ; L-Lactate Dehydrogenase* ; Meningitis* ; Plasminogen ; Pneumonia ; Streptococcal Infections ; Streptococcus pneumoniae* ; Streptokinase

Fibrinolytic Agents ; therapeutic use ; Humans ; Lung Neoplasms ; complications ; Mesothelioma ; complications ; Pleural Effusion, Malignant ; drug therapy ; Streptokinase ; therapeutic use

BACKGROUND: Airway obstruction due to blood clot occurs unusually but in a variety of clinical settings. Initial efforts for removal of the endobronchial blood clot involve flexible bronchoscopic evaluation with saline lavage and suctioning and then forceps extraction. If unsuccessful, further options include rigid bronchoscopy, Fogarty catheter dislogement of the clot, and topical thrombolytic agents. The several successful uses of endobronchial streptokinase or urokinase to dissolve an endobronchial blood clot have been previously reported, but not yet in Korea. Herein we describe a 51-year old man with superior vena cava thrombosis secondary to Behcet's disease who experienced life threatening airway obstruction after hemoptysis due to a large organized blood clot in left main bronchus. Urokinase(260,000 U), injected through a fiberoptic bronchoscope, totally dissolved the clot. No complications occured.
Airway Obstruction ; Bronchi ; Bronchoscopes ; Bronchoscopy ; Catheters ; Fibrinolytic Agents ; Hemoptysis ; Humans ; Korea ; Middle Aged ; Streptokinase ; Suction ; Superior Vena Cava Syndrome ; Surgical Instruments ; Therapeutic Irrigation ; Urokinase-Type Plasminogen Activator*

Femoral artery thrombosis is an uncommon but potentially serious complication following pediatric cardiac catheterization. Treatment options of thrombosis include intravenous heparin infusion, thrombolytic therapy such as streptokinase, urokinase and tissue plasminogen activator, and surgical thrombectomy. These treatments have varying degrees of success and complication. We report successful use of recombinant tissue plasminogen activator for management of femoral artery thrombosis in neonate following transcatheter balloon valvuloplasty of pulmonary valvular stenosis.
Balloon Valvuloplasty ; Cardiac Catheterization ; Cardiac Catheters ; Constriction, Pathologic ; Femoral Artery* ; Heparin ; Humans ; Infant, Newborn* ; Pulmonary Valve Stenosis ; Streptokinase ; Thrombectomy ; Thrombolytic Therapy ; Thrombosis* ; Tissue Plasminogen Activator* ; Urokinase-Type Plasminogen Activator